Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Standard
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. / Lange, Christoph; Abubakar, Ibrahim; Alffenaar, Jan-Willem C; Bothamley, Graham; Caminero, Jose A; Carvalho, Anna Cristina C; Chang, Kwok-Chiu; Codecasa, Luigi; Correia, Ana; Crudu, Valeriu; Davies, Peter; Dedicoat, Martin; Drobniewski, Francis; Duarte, Raquel; Ehlers, Cordula; Erkens, Connie; Goletti, Delia; Günther, Gunar; Ibraim, Elmira; Kampmann, Beate; Kuksa, Liga; de Lange, Wiel; van Leth, Frank; van Lunzen, Jan; Matteelli, Alberto; Menzies, Dick; Monedero, Ignacio; Richter, Elvira; Rüsch-Gerdes, Sabine; Sandgren, Andreas; Scardigli, Anna; Skrahina, Alena; Tortoli, Enrico; Volchenkov, Grigory; Wagner, Dirk; van der Werf, Marieke J; Williams, Bhanu; Yew, Wing-Wai; Zellweger, Jean-Pierre; Cirillo, Daniela Maria.
in: EUR RESPIR J, Jahrgang 44, Nr. 1, 01.07.2014, S. 23-63.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Transfer › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
AU - Lange, Christoph
AU - Abubakar, Ibrahim
AU - Alffenaar, Jan-Willem C
AU - Bothamley, Graham
AU - Caminero, Jose A
AU - Carvalho, Anna Cristina C
AU - Chang, Kwok-Chiu
AU - Codecasa, Luigi
AU - Correia, Ana
AU - Crudu, Valeriu
AU - Davies, Peter
AU - Dedicoat, Martin
AU - Drobniewski, Francis
AU - Duarte, Raquel
AU - Ehlers, Cordula
AU - Erkens, Connie
AU - Goletti, Delia
AU - Günther, Gunar
AU - Ibraim, Elmira
AU - Kampmann, Beate
AU - Kuksa, Liga
AU - de Lange, Wiel
AU - van Leth, Frank
AU - van Lunzen, Jan
AU - Matteelli, Alberto
AU - Menzies, Dick
AU - Monedero, Ignacio
AU - Richter, Elvira
AU - Rüsch-Gerdes, Sabine
AU - Sandgren, Andreas
AU - Scardigli, Anna
AU - Skrahina, Alena
AU - Tortoli, Enrico
AU - Volchenkov, Grigory
AU - Wagner, Dirk
AU - van der Werf, Marieke J
AU - Williams, Bhanu
AU - Yew, Wing-Wai
AU - Zellweger, Jean-Pierre
AU - Cirillo, Daniela Maria
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence.This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
AB - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence.This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
U2 - 10.1183/09031936.00188313
DO - 10.1183/09031936.00188313
M3 - SCORING: Journal article
C2 - 24659544
VL - 44
SP - 23
EP - 63
JO - EUR RESPIR J
JF - EUR RESPIR J
SN - 0903-1936
IS - 1
ER -